Get started
Author

Stefana Stella Impera

Observed names: S Impera, S. Impera, Stefana Impera, Stella Impera
Institution: Ospedale Garibaldi
OpenAlex ID: A5024883827
Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial
2017 · Esther N Oliva, Caterina Alati, et al. · The Lancet Haematology · 164
Differences among young adults, adults and elderly chronic myeloid leukemia patients
2014 · F. Castagnetti, G. Gugliotta, et al. · Annals of Oncology · 96
PDF
Quality of life in elderly patients with acute myeloid leukemia: patients may be more accurate than physicians
2011 · E. N. Oliva, F. Nobile, et al. · Haematologica · 73
PDF
Quality of life and physicians' perception in myelodysplastic syndromes.
2012 · Esther Natalie Oliva, Carlo Finelli, et al. · Europe PMC (PubMed Central) · 61
JAK2V617F allele burden ⩾50% is associated with response to ruxolitinib in persons with MPN-associated myelofibrosis and splenomegaly requiring therapy
2016 · G Barosi, C Klersy, et al. · Leukemia · 53
Darbepoetin alfa for the treatment of anemia associated with myelodysplastic syndromes: efficacy and quality of life
2010 · Esther N. Oliva, Francesco Nobile, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 41
Eltrombopag for Low-Risk Myelodysplastic Syndromes With Thrombocytopenia: Interim Results of a Phase II, Randomized, Placebo-Controlled Clinical Trial (EQOL-MDS)
2023 · Esther Natalie Oliva, Marta Riva, et al. · Journal of Clinical Oncology · 39
PDF
A population‐based study of chronic myeloid leukemia patients treated with imatinib in first line
2016 · Fausto Castagnetti, Francesco Di Raimondo, et al. · American Journal of Hematology · 37
PDF
High BCR–ABL/GUSIS Levels at Diagnosis of Chronic Phase CML Are Associated with Unfavorable Responses to Standard-Dose Imatinib
2017 · Paolo Vigneri, Fabio Stagno, et al. · Clinical Cancer Research · 34
Clinical Implications of Discordant Early Molecular Responses in CML Patients Treated with Imatinib
2019 · Stefania Stella, Valentina Zammit, et al. · International Journal of Molecular Sciences · 23
PDF
Dosing and clinical outcomes of ruxolitinib in patients with myelofibrosis in a real‐world setting: Interim results of the Italian observational study (ROMEI)
2025 · Massimo Breccia, Francesca Palandri, et al. · Cancer · 19
BCR-ABL1 Doubling-Times and Halving-Times May Predict CML Response to Tyrosine Kinase Inhibitors
2019 · Maria Stella Pennisi, Stefania Stella, et al. · Frontiers in Oncology · 17
PDF
Ruxolitinib Adherence in Myelofibrosis and Polycythemia Vera: the “RAMP” Italian multicenter prospective study
2024 · F. Palandri, G. Auteri, et al. · Annals of Hematology · 14
PDF
CD34 Expression in Adult Acute Lymphoblastic Leukemia
1995 · Elio Caccioila, Patrizia Guglielmo, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 14
Eltrombopag for the Treatment of Thrombocytopenia of Low and Intermediate-1 IPSS Risk Myelodysplastic Syndromes: Interim Results on Efficacy, Safety and Quality of Life of an International, Multicenter Prospective, Randomized, Trial
2015 · Esther Natalie Oliva, Valeria Santini, et al. · Blood · 13
Adherence to ruxolitinib, an oral JAK1/2 inhibitor, in patients with myelofibrosis: interim analysis from an Italian, prospective cohort study (ROMEI)
2021 · Paola Guglielmelli, Francesca Palandri, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 12
Beta-1-lntegrin Expression in Adult Acute Lymphoblastic Leukemia: Possible Relationship with the Stem Cell Antigen CD34
2009 · R.R. Cacciola, F. Stagn, et al. · Acta Haematologica · 10
Long Term Effects of Eltrombopag Treatment Versus Placebo for Low-Risk Myelodysplastic Syndromes with Thrombocytopenia (EQoL-MDS): Interim Results of a Single-Blind, Randomised, Controlled, Phase 2 Superiority Trial
2019 · Esther Natalie Oliva, Caterina Alati, et al. · Blood · 9
Real‐World Efficacy Profile of Compassionate Use of Asciminib in an Italian, Multi‐Resistant Chronic‐Phase Chronic Myeloid Leukemia (CML‐CP) Patient Population
2025 · Massimo Breccia, Antonella Russo Rossi, et al. · Hematological Oncology · 8
PDF
Multicenter, Prospective and Retrospective Observational Cohort Study of Ponatinib in Patients with CML in Italy: Primary Analysis of the Oiti Trial
2021 · Massimo Breccia, Luigia Luciano, et al. · Blood · 8
P686: Real-world Efficacy Profile of Asciminib in an Italian, Multi-resistant Chronic-phase Chronic Myeloid Leukemia (cp-cml) Patient Population
2023 · Massimo Breccia, Antonella Russo Rossi, et al. · HemaSphere · 6
P-310 Eltrombopag for the treatment of thrombocytopenia of low and intermediate-1 IPSS risk myelodysplastic syndromes: Results of a prospective, randomized trial
2013 · E.N. Oliva, V. Santini, et al. · Leukemia Research · 6
In Vitro Sensitivity of B-CLL Cells to Fludarabine and Interferons
1995 · Francesco Di Raimondo, GIUSEPPE Albero Palumbo, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 6
High BCR-ABL/GUSIS Levels At Diagnosis Are Associated With Unfavorable Responses To Imatinib
2013 · Paolo G Vigneri, Fabio Stagno, et al. · Blood · 4
High BCR-ABL Levels At Diagnosis Are Associated with Unfavorable Responses to Imatinib Mesylate.
2012 · Paolo G Vigneri, Fabio Stagno, et al. · Blood · 4
Works count: 61
Citation count: 794
H-index: 14
I10-index: 17
Year
Topic
Type